Hainan Poly Pharm Valuation

Is 300630 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300630 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 300630's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 300630's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300630?

Key metric: As 300630 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 300630. This is calculated by dividing 300630's market cap by their current revenue.
What is 300630's PS Ratio?
PS Ratio	3.6x
Sales	CN¥1.31b
Market Cap	CN¥4.63b

300630 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.4x
Enterprise Value/EBITDA	42.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 300630's PS Ratio compare to its peers?

The above table shows the PS ratio for 300630 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8x
000908 Hunan Jingfeng PharmaceuticalLtd	11.7x	n/a	CN¥4.6b
301393 Suzhou Highfine Biotech	11.3x	n/a	CN¥4.8b
300110 Huaren Pharmaceutical	3x	n/a	CN¥4.5b
300006 Chongqing Lummy Pharmaceutical	6x	n/a	CN¥5.1b
300630 Hainan Poly Pharm	3.6x	n/a	CN¥4.6b

Price-To-Sales vs Peers: 300630 is good value based on its Price-To-Sales Ratio (3.6x) compared to the peer average (8x).

Price to Sales Ratio vs Industry

How does 300630's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
600664 Harbin Pharmaceutical Group	0.6x	n/a	US$1.28b
000411 Zhejiang Int'l GroupLtd	0.2x	n/a	US$778.04m
000153 Anhui Fengyuan Pharmaceutical	0.7x	n/a	US$410.83m
600781 FUREN Group PharmaceuticalLtd	0.3x	n/a	US$66.91m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 300630 is expensive based on its Price-To-Sales Ratio (3.6x) compared to the CN Pharmaceuticals industry average (3.6x).

Price to Sales Ratio vs Fair Ratio

What is 300630's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300630 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.6x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 300630's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.31

-1.4%

-24.4%

Sichuan Kelun Pharmaceutical

CN¥48.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.05

3.7%

7.9%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.18

-1.8%

13.3%